E-LIB Suche - Ergebnisse für: KESKİNKILIÇ, MERVE

1

Triple Negative Breast Cancers: An Obsolete Entity?:

Keskinkılıc, Merve ; Gökmen-Polar, Yesim ; Badve, Sunil S.
Clinical Breast Cancer. 24 (2024) 1 - p. 1-6 , 2024

Link: https://doi.org/10.1016/..

2

Is the percentage of hormone receptor positivity in HR+ HER..:

Keskinkilic, Merve ; Semiz, Huseyin Salih ; Yavuzsen, Tugba.
Frontiers in Oncology. 14 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

3

The efficacy of palbociclib and ribociclib in the first-lin..:

Yıldırım, Hasan Çağrı ; Kutlu, Yasin ; Mutlu, Emel...
International Journal of Clinical Oncology. 29 (2024) 3 - p. 258-265 , 2024

Link: https://doi.org/10.1007/..

4

Antibody-Drug Conjugates in Triple Negative Breast Cancer:

Keskinkilic, Merve ; Sacks, Ruth
Clinical Breast Cancer. 24 (2024) 3 - p. 163-174 , 2024

Link: https://doi.org/10.1016/..

5

The comparison of functional status and health-related para..:

Gultekin, Sukriye Cansu ; Cakir, Ahmet Burak ; Guc, Zeynep Gulsum...
Supportive Care in Cancer. 32 (2024) 2 - p. , 2024

Link: https://doi.org/10.1007/..

6

Efficacy of everolimus plus hormonal treatment after cyclin..:

Beypınar, İsmail ; Demir, Hacer ; Yaslıkaya, Şendağ...
Breast Cancer Research and Treatment. , 2024

Link: https://doi.org/10.1007/..

7

The prognostic value of immune-nutritional status in metast..:

Keskinkilic, Merve ; Semiz, Huseyin Salih ; Ataca, Evrim.
Supportive Care in Cancer. 32 (2024) 6 - p. , 2024

Link: https://doi.org/10.1007/..

8

The effect of low HER2 expression on treatment outcomes in ..:

Caliskan Yildirim, Eda ; Atag, Elif ; Coban, Ezgi...
The Breast. 70 (2023) - p. 56-62 , 2023

Link: https://doi.org/10.1016/..

9

Validity and Reliability of the Turkish Version of National..:

Yavuzsen, Husnu Tore ; Gulteki̇n, Sukriye Cansu ; Polat, Karya...
European Journal of Cancer Care. 2023 (2023) - p. 1-8 , 2023

Link: https://doi.org/10.1155/..

10

The Prognostic Nutritional Index (PNI): A New Biomarker for..:

Ellez, Halil Ibrahim ; Keskinkilic, Merve ; Semiz, Hüseyin Salih...
Journal of Clinical Medicine. 12 (2023) 17 - p. 5434 , 2023

Link: https://doi.org/10.3390/..

11

CDK4/6 Inhibition in the Metastatic Setting: Where Are We H..:

Sakach, Elizabeth ; Keskinkilic, Merve ; Wood, Sarah..
Current Treatment Options in Oncology. 24 (2023) 9 - p. 1103-1119 , 2023

Link: https://doi.org/10.1007/..

12

Efficacy of subsequent treatments in patients with hormone-..:

Karacin, Cengiz ; Oksuzoglu, Berna ; Demirci, Ayşe...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

13

Correction: Efficacy of subsequent treatments in patients w..:

Karacin, Cengiz ; Oksuzoglu, Berna ; Demirci, Ayşe...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

14

The percentage of ALK-positive cells and the efficacy of fi..:

Hizal, Mutlu ; Bilgin, Burak ; Paksoy, Nail...
Journal of Cancer Research and Clinical Oncology. 149 (2022) 8 - p. 4141-4148 , 2022

Link: https://doi.org/10.1007/..

15

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) ..:

Yıldırım, Hasan Çağrı ; Mutlu, Emel ; Chalabiyev, Elvin...
The Breast. 66 (2022) - p. 85-88 , 2022

Link: https://doi.org/10.1016/..